Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



This Just In: More Upgrades and Downgrades

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

At The Motley Fool, we poke plenty of fun at Wall Street analysts and their endless cycle of upgrades, downgrades, and "initiating coverage at neutral." The pinstripe-and-wingtip crowd is entitled to its opinions, but we have some pretty sharp stock pickers down here on Main Street, too. And we're not always impressed with how Wall Street does its job.

Perhaps we shouldn't be giving virtual ink to "news" of analyst upgrades and downgrades. And we wouldn't -- if that were all we were doing. But in "This Just In," we don't simply tell you what the analysts said. We also show you whether they know what they're talking about. To help, we've enlisted Motley Fool CAPS, our tool for rating stocks and analysts alike. With CAPS, we track the long-term performance of Wall Street's best and brightest -- and its worst and sorriest, too.

"So long, and thanks for all the fish."
In Douglas Adams' Hitchhiker's Guide to the Galaxy series, readers learn that just before Earth was destroyed, the dolphins sent mankind a parting note before departing our planet for others in less danger of imminent vaporization: "So long, and thanks for all the fish." This morning, RBC Capital sent a similar note to investing mogul Carl Ichan, in the form of a downgrade for Clorox (NYSE: CLX  ) .

As you've probably heard by now, Icahn has offered to buy Clorox -- first sending the board a $76.50 offer for the company's shares and, when that was rejected, upping his bid to $80 yesterday. According to Icahn, there are at least two attractive outcomes here. On one hand, he may succeed in buying the company, rewarding shareholders with a buyout premium and then working his vulture-investor magic to strip off and sell the company's less desirable parts, revealing the tasty, profitable caramel core at the center -- which he would then keep for himself. Alternatively, Icahn suggests that his bid may elicit interest from the likes of Procter & Gamble (NYSE: PG  ) , Unilever (NYSE: UL  ) , Colgate-Palmolive (NYSE: CL  ) , and/or Kimberly-Clark (NYSE: KMB  ) -- any of which might happily pay $100 for this stock that was selling in the $60s just last week.

So far, none of these companies has expressed any interest whatsoever. On Monday, I argued that there will be no counteroffers forthcoming -- and it seems RBC agrees with me. After crunching the numbers, and taking into account the 9% gain Clorox has booked over the past 3.5 days of trading, RBC is downgrading Clorox to "market perform" and moving on in search of better bargains.

Let's go to the tape
Is that the right move -- for RBC, and for you, if you're a Clorox shareholder? Obviously, I think so. I told you on Monday why I think Clorox costs too much at today's $75 price tag, and why it would be even more irrationally exuberant to expect the shares to reach $100. But before you take my word for it, consider the record of the analyst who's now backing my theory: RBC.

According to our CAPS stats, RBC is a fine analyst in many respects and outperforms 95% of the investors we track on CAPS across the length and breadth of its many, many stock picks. There's just one problem with its record, though: RBC does an absolutely miserable job of picking winners in the Household Products industry. Out of five recommendations made over the past few years, RBC's currently beating the market on just two of 'em -- and neither one is named "Clorox":


RBC Rating

CAPS Rating
(out of 5)

RBC's Picks Beating (Lagging) S&P by

Energizer Holdings (NYSE: ENH  ) Outperform **** 15 points
Church & Dwight (NYSE: CHD  ) Outperform **** 3 points
Kimberly-Clark Outperform ***** (2 points)
Colgate Outperform ***** (7 points)
Clorox Outperform ***** (17 points)

I have to say, I'm not best pleased to find myself now in company with RBC. So far, this analyst's track record in Household Products resembles nothing so much as a trail of muddy footprints across a freshly vacuumed rug. Call me a cynic, but I wonder whether RBC is really downgrading Clorox because it lacks confidence in the potential for a buyout. I suspect that RBC is instead using the Icahn bump as a chance to exit a losing position with some dignity.

Foolish takeaway
Be that as it may, I have no particular axe to grind here. I've never recommended Clorox before. To the contrary, I thought the company's decision to acquire Burt's Bees a few years back was a silly mistake and a bad fit for the Baron of Bleach -- and I said as much. As for today, I'm sticking with my original analysis: Clorox's amalgamation of brands, each outstanding on its own, makes little sense in their current configuration.

If Icahn can spur management to make him go away by selling off the company's food brands to Smucker, for example, and its personal-care businesses to P&G -- great. I think a rationalization of the brands would unlock value at Clorox, and that would be good news for today's shareholders. As for the idea that some white knight will ride forth to buy Clorox for $100 a share, though -- well that is still just a pipe dream.

If you were thinking about buying the stock for this reason, then take my advice, and RBC's: Don't.

Fool contributor Rich Smith does not own shares of (or short) any company named above. You can find him on CAPS, publicly pontificating under the handle TMFDitty, where he's currently ranked No. 582 out of more than 170,000 members.

Speaking of which, we should probably mention that not everyone agrees with Rich. In fact, The Motley Fool itself owns shares of Clorox. Motley Fool newsletter services have recommended buying shares of Procter & Gamble, Kimberly-Clark, Unilever, Clorox, and Endurance Specialty Holdings.

We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1523037, ~/Articles/ArticleHandler.aspx, 10/25/2016 10:54:58 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 hour ago Sponsored by:
DOW 18,169.27 -53.76 -0.30%
S&P 500 2,143.16 -8.17 -0.38%
NASD 5,283.40 -26.43 -0.50%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/25/2016 4:02 PM
CHD $48.11 Up +0.78 +1.65%
Church and Dwight CAPS Rating: ***
CL $71.31 Up +0.28 +0.39%
Colgate-Palmolive CAPS Rating: ****
CLX $119.58 Up +0.92 +0.78%
The Clorox Company CAPS Rating: ****
ENH $91.90 Down +0.00 +0.00%
Endurance Specialt… CAPS Rating: *****
KMB $113.73 Down -0.18 -0.16%
Kimberly-Clark CAPS Rating: ****
PG $86.97 Up +2.87 +3.41%
Procter and Gamble CAPS Rating: ****
UL $42.31 Down -0.12 -0.28%
Unilever CAPS Rating: *****